

BIOGRAPHICAL SKETCH

Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2.
Follow this format for each person. **DO NOT EXCEED FOUR PAGES.**

NAME Andrei lagaru, M.D.	POSITION TITLE Assistant Professor of Radiology		
eRA COMMONS USER NAME Andrei.lagaru			
EDUCATION/TRAINING <i>(Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)</i>			
INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
"C.A. Rosetti" High School Bucharest, Romania	Baccalaureate	1994	Mathematics/Physics
"Carol Davila" Medical School Bucharest, Romania	M.D.	1994-2000	Medicine
Drexel University College of Medicine, Philadelphia, PA		2003-2004	Internal Medicine
Keck School of Medicine of USC Los Angeles, CA		2004-2005	Nuclear Medicine
Stanford University Medical Center, Stanford, CA		2005-2006	Nuclear Medicine
Stanford University Medical Center, Stanford, CA		2006-2007	PET/CT

NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the attached sample.

A. Personal Statement

I have extensive, relevant research background and publication history in Nuclear Medicine and a passion for new imaging modalities. Likewise, I am committed to the use of translational research using molecular imaging techniques that can help promulgate the advances from our field to other areas of medicine and throughout the biomedical research community. Ultimately, I envision Molecular Imaging not only as a clinical reality, but also as a significant force on early diagnosis and management of cancer in the 21st century.

B. Positions and Honors**Positions**

2007-2010 Instructor, Department of Radiology, Stanford University Medical Center, Stanford, CA
2010-present Assistant Professor, Department of Radiology, Stanford University Medical Center, Stanford, CA

Honors

2007 Travel Grant Award, ACNP Annual Meeting
2008 Best Essay Award, ACNP Annual Meeting
2008 Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine
2008 Outstanding Teaching Award, Stanford Radiology Residency Program
2009 Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine
2009 Image of the Year Award, Society of Nuclear Medicine
2009 Developmental Cancer Research Award, Stanford Cancer Center
2009 MD/Scientist Award, Western Regional SNM Annual Meeting
2010 Best Essay Award, ACNM Annual Meeting
2010 Alavi-Mandell Award, Society of Nuclear Medicine, The Journal of Nuclear Medicine
2011 Best Essay Award, ACNM Annual Meeting

C. Selected peer-reviewed publications (in chronological order). Selected from 36 peer-reviewed publications.

- lagaru A**, Quon A, McDougall IR, Gambhir SS. Merkel Cell Carcinoma: Is There a Role for ¹⁸F FDG PET/CT? *Mol Imaging Biol.* 2006 Jul-Aug;8(4):212-7.
- lagaru A**, Masamed R, Singer PA, Conti PS. ¹⁸F FDG PET and PET/CT Diagnosis of Patients with Recurrent Papillary Thyroid Cancer. *Mol Imaging Biol.* 2006 Sep-Oct;8(5):309-14.

Principal Investigator/Program Director (Last, First, Middle): **lagaru, Andrei**

3. **lagaru A**, Chawla SP, Menendez LR, Conti PS. ¹⁸F FDG PET and PET/CT for Detection of Pulmonary Metastases from Musculoskeletal Sarcomas. Nucl Med Commun. 2006 Oct;27(10):795-802.
4. **lagaru A**, Quon A, McDougall IR, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas. Clin Nucl Med. 2006 Dec;31(12):754-760.
5. **lagaru A**, Quon A, Johnson D, Gambhir SS, McDougall IR. ¹⁸F FDG PET/CT in the Management of Melanoma. Mol Imaging Biol. 2007 Jan-Feb;9(1):50-7.
6. **lagaru A**, Masamed R, Keesara S, Conti PS. Breast MRI and ¹⁸F FDG PET/CT in the Management of Breast Cancer. Ann Nucl Med. 2007 Jan;21(1):33-8.
7. **lagaru A**, Masamed R, Singer PA, Conti PS. Detection of Occult Medullary Thyroid Cancer Recurrence with ¹⁸F FDG PET and PET/CT. Mol Imaging Biol. 2007 Mar-Apr;9(2):72-7.
8. **lagaru A**, Kalinyak J, McDougall IR. ¹⁸F FDG PET/CT in the Management of Thyroid Cancer. Clin Nucl Med. 2007 Sep;32(9):690-5.
9. **lagaru A**, Masamed R, Chawla S, Menendez L, Fedenko A, Conti PS. ¹⁸F FDG PET and PET/CT Evaluation of Response to Neoadjuvant Chemotherapy in Musculoskeletal and Soft-Tissue Sarcomas. Clin Clin Nucl Med. 2008 Jan;33(1):8-13.
10. **lagaru A**, Gambhir SS, Goris ML. ⁹⁰Y-Ibritumomab (Zevalin[®]) Therapy in Refractory Non-Hodgkin's Lymphoma: Observations from ¹¹¹In-Ibritumomab Pre-Treatment Imaging. J Nucl Med. 2008 Nov;49(11):1809-1812.
11. **lagaru A**, Mitra ES, McDougall IR, Quon A, Gambhir SS. ¹⁸F FDG PET/CT Evaluation of Patients with Ovarian Carcinoma. Nucl Med Commun. 2008 Dec;29(12):1046-51.
12. **lagaru A**, Mitra ES, Yaghoubi S, Dick DW, Quon A, Goris ML, Gambhir SS. A Novel Strategy for a Cocktail ¹⁸F Fluoride and ¹⁸F FDG PET/CT Scan for Evaluation of Malignancy: Results of the Pilot Phase Study. J Nucl Med. 2009 Apr;50(4):501-505.
13. Mitra ES, El-Maghraby T, Rodriguez CA, Quon A, McDougall IR, Gambhir SS, **lagaru A**. Efficacy of ¹⁸F-FDG PET/CT in the Evaluation of Patients with Recurrent Cervical Carcinoma. Eur J Nucl Med Mol Imaging. 2009 Jul 8 [Epub ahead of print].
14. **lagaru A**, Mitra ES, Ganjoo K, Knox SJ, Goris ML. ¹³¹I-Tositumomab (Bexxar[®]) vs. ⁹⁰Y-Ibritumomab (Zevalin[®]) Therapy of Refractory/Relapsed Non-Hodgkin Lymphoma. Mol Imaging Biol. 2010 Apr;12(2):198-203.
15. **lagaru A**, Mitra ES, Gambhir SS. ¹⁸F FDG PET/CT in Cancers of the Head and Neck: What is the Definition of Whole-Body Scanning? Mol Imaging Biol. 2010 May 22. [Epub ahead of print]

C. Research Support

Funding Agency: Genentech
Period: 5/1/08 – 10/31/09
Grant Title: PET Imaging of Lymphoma Patients Using Radiolabeled Rituximab
Principal Investigator: Sanjiv Sam Gambhir, MD, PhD
Co- Investigator: Andrei lagaru, MD
Goal: Identify a novel radiopharmaceutical specific for CD20 expressing B-cell lymphomas
Costs: \$585,000.00
Percent Effort: 25%

Funding Agency: Ivy Foundation
Period: 10/01/09 - 09/30/12
Grant Title: ¹⁸F FPPRGD2 PET/CT, ¹⁸F FDG PET/CT and MRI Evaluation of Response to Anti-Angiogenesis Therapy in Recurrent Glioblastoma Multiforme
Principal Investigator: Sanjiv Sam Gambhir, MD, PhD
Co-Investigator: Andrei lagaru, MD
Goal: Using ¹⁸F FPPRGD2 PET/CT to evaluate GBM
Costs: \$1,500,000.00
Percent Effort: 5%

Funding Agency: NIH
Period: 10/01/10 - 09/30/15
Title: Monitoring Response to Targeted Therapy in Non-Small Cell Lung Cancer using ¹⁸F FPPRGD2 PET/CT and *In-Vitro* Diagnostics

Principal Investigator/Program Director (Last, First, Middle): **lagaru, Andrei**

Principal Investigator: Sanjiv Sam Gambhir, MD, PhD
Co-Investigator: Andrei lagaru, MD
Goal: To evaluate a new integrin receptor PET radiopharmaceutical for evaluation of response to anti-angiogenesis therapy in patients with NSCLC
Costs: \$2,500,000.00
Percent Effort: 10%